Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

China Biobetter EPO Deal Seen Boosting Genexine’s Prospects

This article was originally published in PharmAsia News

Executive Summary

Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.

Advertisement

Related Content

Should Pharma Be Concerned About Cooling China-Korea Ties?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register